Divi’s Laboratories Limited shares jumped nearly 5% in morning trade following the release of strong Q4 FY25 results.
The company reported a 23% year-on-year (YoY) rise in consolidated net profit to ₹662 crore for the quarter ended March 31, 2025, compared to ₹538 crore in Q4 FY24. The impressive growth was supported by higher sales and better operational efficiency.
Revenue from operations rose 12% YoY to ₹2,585 crore, up from ₹2,303 crore in the same period last year. Total income for the quarter stood at ₹2,671 crore, compared to ₹2,382 crore in Q4 FY24. The company’s EBITDA increased to ₹869 crore from ₹808 crore, with a stable EBITDA margin of 32.5%.
Despite a rise in total expenses to ₹1,807 crore, driven by higher material and employee costs, Divi’s posted a profit before tax of ₹864 crore—up from ₹713 crore a year ago.
For the full financial year FY25, Divi’s Laboratories reported a net profit of ₹2,191 crore, marking a robust 37% increase from ₹1,600 crore in FY24. Total income for the year rose to ₹9,712 crore from ₹8,184 crore.
In the meantime, Nuvama has reiterated a Buy on Divi’s Labs with a target of ₹7,225, implying a ~15% upside from the current price of ₹6,268. Strong Q4 margins and growth in API and nutraceuticals segments were key positives. Operations have begun at Unit-III (₹1,500 crore capex), and the GLP-1 intermediate opportunity could add $100–175 million annually upon commercialisation, as per Nuvama.
Divi’s Laboratories shares opened at ₹6,400 and surged to a high of ₹6,656, marking a new 52-week high. The stock also touched a low of ₹6,333.50 during the session. This performance reflects a significant uptrend, especially considering the 52-week low of ₹3,850.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
